Latest Biologic Stories
For the Treatment of Severe Ulcerative Colitis, Remicade Holds a Strong Lead Over Humira, According to a New Report from BioTrends Research Group EXTON, Pa., May 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Janssen/Merck/Mitsubishi Tanabe's Remicade is the market leader for the treatment of ulcerative colitis in the EU5 (France, Germany, Italy, Spain and the United...
AUSTIN, Texas, May 1, 2013 /PRNewswire/ -- XBiotech announced today that John Simard, Chairman, President & Chief Executive Officer, will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20(th) at 1:30pm ET. The conference will take place at the Sheraton New York Hotel May 20-22, 2013. John Simard remarked "XBiotech is delighted to be invited by UBS to present at this prestigious venue. UBS is one of the greatest financial institutions in the world...
MISSISSAUGA, ON, April 30, 2013 /CNW/ - Amgen, a biotechnology company developing both innovative biologic and biosimilar medicines, welcomes a new report from the European Commission detailing Europe's strong regulatory and commercial foundation for biosimilars in the healthcare marketplace. The report shows that biosimilars are helping improve competition and thus may be increasing access to biologic medicines for patients. The science-led regulatory framework in the European...
LADERA RANCH, Calif., April 29, 2013 /PRNewswire/ -- Advanced Biologics announced today that they will be presenting expanded data at the American Academy of Neurosurgeons (AANS) meeting this week in New Orleans, LA showcasing a clinical study demonstrating superior lumbar fusion rates for OsteoAMP® when compared to rhBMP-2 (Infuse®, Medtronic). In a blinded, multi-center clinical and radiological study, fusion analysis showed superiority for OsteoAMP® in producing fusions when...
Surveyed US Rheumatologists Believe Actemra is Most at Risk for Displacement by Xeljanz, According to a New Report from BioTrends Research Group EXTON, Pa., April 24 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. rheumatologists believe that--at three months post launch--initiations of Pfizer's Xeljanz in the rheumatoid arthritis (RA) treatment...
BEIJING, April 24, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has donated 500 bottles of human albumin and 1000 bottles of Tetanus immunoglobulin through its Shandong Taibang subsidiary for those injured in the devastating earthquake that struck Lushan County, Ya'an City located in China's Sichuan province on April...
CAMBRIDGE, England, April 22, 2013 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company, announced today an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab's proprietary Kymouse(TM) human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases. The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL...
PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA The agreement covers the initiation of development activities by DSM for DecImmune's lead monoclonal antibody program. The initial development will be performed at DSM Biologics'...
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that their new cGMP custom biopharmaceutical manufacturing 'biologics plant of the future' will open in June 2013. PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- The DSM facility was built with cooperation from the Queensland and Commonwealth Governments of Australia. Karen King, President of DSM Biologics, the biopharmaceutical manufacturing...
ROCKVILLE, Md., April 19, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, reiterated that the Exclusive Channel Collaboration Agreement dated August 6, 2012 between the Company and Intrexon Corporation (Intrexon) remains in effect, as stated earlier today. This Exclusive Channel Collaboration Agreement governs a "channel collaboration" arrangement for the use of Intrexon's...
